The potential adverse effects of hypodermic glucagon‐like peptide ‐1 receptor agonist on patients with type 2 diabetes: A population‐based study

Abstract Background Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs), a class of injectable antidiabetic drugs, have shown significant efficacies in improving glycemic and weight control in patients with type 2 diabetes (T2D). However, the long‐term safety of GLP‐1 RAs remains insufficiently st...

Volledige beschrijving

Bibliografische gegevens

Hoofdauteurs:	Zhiyuan Cheng, Shuang Wang, Fu‐rong Li, Cheng Jin, Chunbao Mo, Jing Zheng, Xia Li, Fengchao Liang, Jinkui Yang, Dongfeng Gu
Formaat:	Artigo
Taal:	Inglês
Gepubliceerd in:	Wiley 2024-10-01
Reeks:	Journal of Diabetes
Onderwerpen:	clinical adverse outcomes GLP‐1 receptor agonists type 2 diabetes
Online toegang:	https://doi.org/10.1111/1753-0407.70013
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!